Milestone Pharmaceuticals Inc. MIST
We are a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Our approved product CARDAMYSTTM (etripamil) nasal spray is available in the United States and is the first and only FDA approved self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. We continue to seek, either directly or through collaboration with our partners, marketing approval from regulatory agencies responsible for regions outside the United States. We are also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate, or "AFib-RVR."
We are currently focusing our efforts and financial resources on (i) the commercialization of CARDAMYSTTM (etripamil) nasal spray for the treatment of PSVT, (ii) the development of etripamil for the treatment of AFib-RVR and (iii) corporate development activities that have the potential to increase company value through strategic collaborations.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| R&D | $18.1M | $14.4M | $31.1M | $39.8M | $38.7M | $34.5M | $42.0M | $16.8M | — |
| SG&A | $17.3M | $16.7M | $15.9M | $15.7M | $12.4M | $10.3M | $7.0M | $3.1M | — |
| Operating income | -$62.1M | -$42.1M | -$61.1M | -$59.6M | -$43.1M | -$50.7M | -$57.9M | -$23.8M | — |
| Interest expense | $3.8M | $3.6M | $2.6M | — | — | — | — | — | — |
| Pre-tax income | -$63.1M | -$41.5M | -$59.7M | -$58.4M | -$42.9M | -$50.0M | -$55.3M | -$23.1M | — |
| Income tax | — | — | — | — | — | $17.0K | $56.0K | $74.0K | — |
| Net income | -$63.1K | -$41.5K | -$59.7K | -$58.4M | -$42.9M | -$50.0M | -$55.2M | -$23.2M | — |
| EPS, basic | -0.75 | -0.67 | -1.39 | -1.38 | -1.02 | -1.70 | — | — | — |
| EPS, diluted | -0.75 | -0.67 | -1.39 | -1.38 | -1.02 | -1.70 | -3.50 | 72.63 | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $73.0M | $25.3M | $13.8M | $7.6M | $114.1M | $72.3M | $119.8M | $85.9M | $10.9M |
| Short-term investments | $32.9M | $44.4M | $52.2M | $56.9M | $0 | $70.0M | — | $29.0K | — |
| Inventory | $648.0K | — | — | — | — | — | — | — | — |
| Total current assets | $111.9M | $73.9M | $73.0M | $71.8M | $118.9M | $148.7M | $122.5M | $88.1M | — |
| Property, plant and equipment | $511.0K | $197.0K | $277.0K | $257.0K | $215.0K | $308.0K | $405.0K | $30.0K | — |
| Total assets | $113.6M | $75.5M | $75.2M | $74.5M | $119.8M | $150.0M | $123.4M | $88.1M | — |
| Accounts payable | $13.3M | $7.6M | $6.7M | $5.6M | $6.6M | $5.9M | $8.0M | $4.5M | — |
| Total current liabilities | $14.0M | $8.1M | $7.2M | $6.1M | $6.8M | $6.2M | $8.3M | $4.5M | — |
| Long-term debt | $57.2M | $53.4M | $49.8M | — | — | — | $0 | — | — |
| Total liabilities | $71.8M | $62.4M | $58.5M | $8.1M | $7.2M | $6.9M | $8.5M | $4.5M | — |
| Retained earnings | -$430.6M | -$367.5M | -$326.0M | -$266.3M | -$208.0M | -$163.5M | -$113.5M | -$58.3M | — |
| Total equity | $41.8M | $13.1M | $16.8M | $66.3M | $112.6M | $143.1M | $114.9M | $83.5M | $26.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$49.0M | -$28.8M | -$46.4M | -$52.5M | -$33.2M | -$50.7M | -$51.2M | -$21.0M | — |
| Depreciation and amortisation | $114.0K | $105.0K | $92.0K | $89.0K | $93.0K | $97.0K | $38.0K | $10.0K | — |
| Stock-based compensation | $7.5M | $5.8M | $9.5M | $9.0M | $7.3M | $4.9M | $1.2M | $633.0K | — |
| Capital expenditure | $302.0K | $33.0K | $112.0K | $272.0K | — | — | $413.0K | $5.0K | — |
| Investing cash flow | $11.2M | $8.3M | $4.8M | -$57.1M | $70.0M | -$70.0M | -$384.0K | $16.0M | — |
| Financing cash flow | $85.5M | $32.1M | $47.8M | $3.1M | $5.1M | $73.2M | $85.4M | $80.1M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-052880.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Net income | — | -$23.2M | -$55.2M | -$50.0M | -$42.9M | -$58.4M | -$59.7K | -$41.5K | -$63.1K |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Other event Item 8.01
- Other event Item 8.01
- Other event Item 8.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |